CY1112105T1 - Immunogenic Bacterial Bladders with External Membrane Proteins - Google Patents

Immunogenic Bacterial Bladders with External Membrane Proteins

Info

Publication number
CY1112105T1
CY1112105T1 CY20111100796T CY111100796T CY1112105T1 CY 1112105 T1 CY1112105 T1 CY 1112105T1 CY 20111100796 T CY20111100796 T CY 20111100796T CY 111100796 T CY111100796 T CY 111100796T CY 1112105 T1 CY1112105 T1 CY 1112105T1
Authority
CY
Cyprus
Prior art keywords
bacterium
mlta
membrane proteins
provides
bladders
Prior art date
Application number
CY20111100796T
Other languages
Greek (el)
Inventor
Jeannette Adu-Bobie
Mariagrazia Pizza
Nathalie Norais
Germano Ferrari
Guido Grandi
Original Assignee
Novartis Vaccines And Diagnostics S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines And Diagnostics S.R.L. filed Critical Novartis Vaccines And Diagnostics S.R.L.
Publication of CY1112105T1 publication Critical patent/CY1112105T1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245Escherichia (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1051Hexosyltransferases (2.4.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0258Escherichia
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Η εξάλειψη του μηνιγγιτιδοκοκκικού ομολόγου mltA δίνει βακτηρίδια που αυθόρμητα απελευθερώνουν κυστίδια, τα οποία είναι πλούσια σε ανοσογόνες πρωτεΐνες εξωτερικής μεμβράνης και που μπορούν να προκαλέσουν διασταυρούμενες προστατευτικές αποκρίσεις αντισωμάτων με υψηλότερους βακτηριοκτόνους τίτλους από εκείνους των OMV που παρασκευάστηκαν μέσω των κανονικών διαδικασιών παραγωγής. Κατά συνέπεια, η εφεύρεση παρέχει ένα βακτήριο που έχει μια μετάλλαξη εξάλειψης του mltA γονιδίου του. Η εφεύρεση παρέχει επίσης ένα βακτήριο, το οποίο βακτήριο: (i) έχει ένα κύτταρο που περιέχει πεπτιδογλυκάνη και (ii) δεν εκφράζει πρωτεΐνη που έχει τη λυτική δράση τρανς-γλυκοσυλάσης MltA πρωτεΐνης. Η εφεύρεση παρέχει επίσης συνθέσεις που περιλαμβάνουν κυστίδια τα οποία, κατά τη διάρκεια της καλλιέργειας των βακτηρίων της εφεύρεσης, απελευθερώνονται μέσα στο μέσο της καλλιέργειας.Deletion of the meningitococcal homolog mltA gives bacteria that spontaneously release vesicles, which are rich in immunogenic outer membrane proteins and which can induce cross-protective antibody responses to those produced by higher bacterial strains. Accordingly, the invention provides a bacterium having a deletion mutant of its mltA gene. The invention also provides a bacterium, which bacterium: (i) has a peptidoglycan-containing cell and (ii) does not express a protein having the lysate trans-glycosylase MltA protein. The invention also provides compositions comprising vesicles which, during culture of the bacteria of the invention, are released into the culture medium.

CY20111100796T 2004-10-29 2011-08-18 Immunogenic Bacterial Bladders with External Membrane Proteins CY1112105T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0424092.5A GB0424092D0 (en) 2004-10-29 2004-10-29 Immunogenic bacterial vesicles with outer membrane proteins
EP05801788A EP1804834B1 (en) 2004-10-29 2005-10-28 Immunogenic bacterial vesicles with outer membrane proteins

Publications (1)

Publication Number Publication Date
CY1112105T1 true CY1112105T1 (en) 2015-11-04

Family

ID=33515801

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100796T CY1112105T1 (en) 2004-10-29 2011-08-18 Immunogenic Bacterial Bladders with External Membrane Proteins

Country Status (15)

Country Link
US (3) US9206399B2 (en)
EP (2) EP2279747B1 (en)
JP (4) JP5362221B2 (en)
CN (1) CN101048175B (en)
AT (1) ATE510559T1 (en)
AU (1) AU2005298332B2 (en)
BR (1) BRPI0517514A8 (en)
CA (1) CA2584778C (en)
CY (1) CY1112105T1 (en)
ES (1) ES2507499T3 (en)
GB (1) GB0424092D0 (en)
NZ (1) NZ553989A (en)
PL (1) PL2279747T3 (en)
PT (1) PT2279747E (en)
WO (1) WO2006046143A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2270173T3 (en) 1999-05-19 2016-03-07 Glaxosmithkline Biolog Sa Neisserial combination compositions
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
MX339524B (en) 2001-10-11 2016-05-30 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
ES2385045T3 (en) 2005-02-18 2012-07-17 Novartis Vaccines And Diagnostics, Inc. Urotogenic Escherichia coli immunogens
EP1872791A1 (en) * 2006-06-30 2008-01-02 Institut Pasteur Use of bacterial polysaccharides for biofilm inhibition
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
AR064642A1 (en) 2006-12-22 2009-04-15 Wyeth Corp POLINUCLEOTIDE VECTOR THAT INCLUDES IT RECOMBINATING CELL THAT UNDERSTANDS THE VECTOR POLYPEPTIDE, ANTIBODY, COMPOSITION THAT UNDERSTANDS THE POLINUCLEOTIDE, VECTOR, RECOMBINATING CELL POLYPEPTIDE OR ANTIBODY, USE OF THE COMPOSITION AND A COMPOSITION AND A METHOD
GB0816284D0 (en) * 2008-09-05 2008-10-15 Nat Biolog Standards Board Vaccine
CN102300585A (en) 2008-12-17 2011-12-28 诺华有限公司 Meningococcal vaccines including hemoglobin receptor
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
WO2011039631A2 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
WO2011043538A2 (en) * 2009-10-08 2011-04-14 주식회사이언메딕스 Composition comprising extracellular membrane vesicles derived from indoor air, and use thereof
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
SI3246044T2 (en) 2010-08-23 2024-06-28 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
GB201014967D0 (en) * 2010-09-09 2010-10-20 Univ Southampton Composition
CA2810971C (en) * 2010-09-10 2020-11-03 Novartis Ag Developments in meningococcal outer membrane vesicles
ES2585328T5 (en) 2010-09-10 2022-12-14 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
EP2707009A1 (en) 2011-05-12 2014-03-19 Novartis AG Antipyretics to enhance tolerability of vesicle-based vaccines
US20140336366A1 (en) * 2011-09-06 2014-11-13 Glycovaxyn Ag Bioconjugate vaccines made in prokaryotic cells
ES2654613T3 (en) * 2012-02-02 2018-02-14 Glaxosmithkline Biologicals Sa Promoters for increased protein expression in meningococci
EP2823312B1 (en) 2012-03-08 2019-08-07 GlaxoSmithKline Biologicals SA In vitro potency assay for protein-based meningococcal vaccines
SA115360586B1 (en) 2012-03-09 2017-04-12 فايزر انك Neisseria meningitidis compositions and methods thereof
RU2665841C2 (en) 2012-03-09 2018-09-04 Пфайзер Инк. Neisseria meningitidis compositions and methods of use thereof
WO2013186753A1 (en) 2012-06-14 2013-12-19 Novartis Ag Vaccines for serogroup x meningococcus
JP6324961B2 (en) 2012-09-06 2018-05-16 ノバルティス アーゲー Combination vaccine of serogroup B meningococcus and D / T / P
AU2013320313B2 (en) 2012-09-18 2018-07-12 Glaxosmithkline Biologicals Sa Outer membrane vesicles
US20160120818A1 (en) * 2013-02-07 2016-05-05 Glaxosmithline Biological Sa Pharmaceutical compositions comprising vesicles
JP6446377B2 (en) 2013-03-08 2018-12-26 ファイザー・インク Immunogenic fusion polypeptide
EP3041502A2 (en) 2013-09-08 2016-07-13 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CA2940447C (en) 2014-02-28 2023-07-11 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
RU2723045C2 (en) 2015-02-19 2020-06-08 Пфайзер Инк. Compositions of neisseria meningitidis and methods for preparation thereof
EP3263695A1 (en) * 2016-06-29 2018-01-03 GlaxoSmithKline Biologicals SA Immunogenic compositions
US12109259B2 (en) 2016-09-02 2024-10-08 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
CN108220267B (en) * 2016-12-22 2022-10-04 丰益(上海)生物技术研发中心有限公司 Phospholipase and application thereof
IL267733B2 (en) 2017-01-31 2023-10-01 Pfizer Neisseria meningitidis compositions and methods thereof
KR20200053531A (en) 2017-09-08 2020-05-18 에벨로 바이오사이언시즈, 인크. Bacterial extracellular vesicle
KR20200136361A (en) 2017-12-04 2020-12-07 드 슈타트 데르 네덜란덴, 베르테겐부어디그트 두어 드 미니스터 반 베이웨이에스, 미니스테리 반 폭스겐트존하이트, 벨지인 엔 스포츠 An improved method for the generation of adventitial vesicles
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
CA3126492A1 (en) * 2019-01-11 2020-07-16 Northwestern University Bioconjugate vaccines synthesis in prokaryotic cell lysates
BR112021016605A2 (en) * 2019-02-22 2022-01-18 Evelo Biosciences Inc Bacterial membrane preparations
EP3799884A1 (en) * 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
CN111440748A (en) * 2020-05-15 2020-07-24 黑龙江八一农垦大学 Method for separating, purifying and identifying necrobacillus outer membrane vesicles
CA3204887A1 (en) * 2020-12-11 2022-06-16 Glaxosmithkline Biologicals Sa Hyper-blebbing bacteria
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
WO2023097652A1 (en) * 2021-12-03 2023-06-08 National Center For Nanoscience And Technology An engineered cell and application thereof
GB202211033D0 (en) 2022-07-28 2022-09-14 Glaxosmithkline Biologicals Sa Purification process

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (en) 1978-11-11 1980-05-22 Behringwerke Ag METHOD FOR PRODUCING MEMBRANE PROTEINS FROM NEISSERIA MENINGITIDIS AND VACCINE CONTAINING THEM
SE8205892D0 (en) 1982-10-18 1982-10-18 Bror Morein IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
RU2023448C1 (en) 1987-07-30 1994-11-30 Сентро Насьональ Де Биопрепарадос Method for manufacturing vaccine against various pathogenic serotypes of group b neisser's meningitis
AU631377B2 (en) 1988-08-25 1992-11-26 Liposome Company, Inc., The Affinity associated vaccine
DE3841091A1 (en) 1988-12-07 1990-06-13 Behringwerke Ag SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE
ES2070312T5 (en) 1988-12-19 2003-05-16 American Cyanamid Co CLASS 1 MENINGOCOCIC EXTERNAL MEMBRANE PROTEIN VACCINE.
ES2055785T3 (en) 1989-01-17 1994-09-01 Eniricerche Spa SYNTHETIC PEPTIDES AND THEIR USE AS UNIVERSAL VEHICLES FOR THE PREPARATION OF IMMUNOGENOUS CONJUGATES SUITABLE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES.
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
JPH04506662A (en) 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー Cytokinin and hormone carriers for conjugate vaccines
IT1237764B (en) 1989-11-10 1993-06-17 Eniricerche Spa SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES.
SE466259B (en) 1990-05-31 1992-01-20 Arne Forsgren PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE
EP0471177B1 (en) 1990-08-13 1995-10-04 American Cyanamid Company Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
US5993826A (en) 1993-03-02 1999-11-30 Board Of Regents, The University Of Texas Methods and compositions relating to useful antigens of moraxella catarrhalis
IT1262896B (en) 1992-03-06 1996-07-22 CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES.
ES2143716T3 (en) 1992-06-25 2000-05-16 Smithkline Beecham Biolog VACCINE COMPOSITION CONTAINING ADJUVANTS.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
NL9201716A (en) 1992-10-02 1994-05-02 Nederlanden Staat Outer membrane vesicle comprising a group of polypeptides which have at least the immune function of membrane bound outer membrane proteins (OMPs), method of preparation thereof and a vaccine comprising such an outer membrane vesicle.
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
DK0624376T3 (en) 1993-05-13 2000-07-24 American Cyanamid Co Preparation and use of LOS-depleted outer membrane proteins of gram-negative cocci
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995029662A2 (en) 1994-04-20 1995-11-09 U.S. Department Of The Army Vaccine against gram-negative bacterial infections
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (en) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
AU707131B2 (en) 1995-08-04 1999-07-01 University Of Guelph Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
KR20010021953A (en) 1997-07-17 2001-03-15 추후제출 Immunogenic conjugates comprising a group b meningococcal porin and an h. influenzae polysaccharide
AU755462B2 (en) 1997-08-21 2002-12-12 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Novel mutants of gram negative mucosal bacteria and application thereof in vaccines
DE69815692T2 (en) 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. OIL IN WATER EMULSIONS WITH SAPONINES
KR20010032336A (en) 1997-11-21 2001-04-16 브랑디 빠스깔 Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
KR100769103B1 (en) 1997-11-28 2007-10-23 세로노 제네틱스 인스티튜트 에스.에이. Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
AU759391B2 (en) 1998-02-12 2003-04-10 Wyeth Holdings Corporation Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
JP2002511423A (en) 1998-04-09 2002-04-16 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム vaccine
US8007815B1 (en) 1998-05-29 2011-08-30 Novartis Ag Combination meningitidis B/C vaccines
EP1741443B1 (en) 1998-05-29 2014-05-21 Novartis Vaccines and Diagnostics, Inc. Combination meningitidis B/C vaccines
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
CA2773698C (en) 1998-10-16 2015-05-19 Glaxosmithkline Biologicals S.A. Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
JP2002529069A (en) 1998-11-12 2002-09-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Chlamydia pneumoniae genome sequence
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
CA2371928C (en) 1999-02-22 2013-08-13 Microbiological Research Authority Neisserial vaccine compositions and methods
HU228499B1 (en) 1999-03-19 2013-03-28 Smithkline Beecham Biolog Streptococcus vaccine
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
CO5200837A1 (en) 1999-09-24 2002-09-27 Smithkline Beecham Corp VACCINES
PL355232A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
CN1416352B (en) 2000-01-17 2011-05-25 启龙股份公司 Outer membrane vesicle (OMV) vaccine comprising N. Meningitidis serogroup B outer membrane
CA2396871A1 (en) 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
MXPA02008314A (en) 2000-02-28 2002-12-09 Chiron Spa Heterologous expression of neisserial proteins.
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
NO20002828D0 (en) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinaceous vaccine against Neisseria meningtidis serogroup and method of preparation thereof
CA2414884A1 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
GB0017149D0 (en) 2000-07-12 2000-08-30 Chiron Spa Helicobacter pylori mutants
MXPA03000822A (en) * 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis.
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
ES2298269T3 (en) 2000-09-26 2008-05-16 Idera Pharmaceuticals, Inc. MODULATION OF THE IMMUNO-STIMULATING ACTIVITY OF OLIGONUCLEOTIDIC ANALOGS IMMUNO-STIMULANTS THROUGH POSITIONAL CHEMICAL CHANGES.
EP1328543B1 (en) 2000-10-27 2009-08-12 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups a & b
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
CA2452720C (en) 2001-07-26 2012-04-17 Chiron S.R.L. Vaccines comprising aluminium adjuvants and histidine
DE60234375D1 (en) 2001-09-14 2009-12-24 Cytos Biotechnology Ag PACKAGING IMMUNSTIMULATING CpG IN VIRUS LIKE PARTICLES: PREPARATION METHOD AND USE
CA2492823A1 (en) 2001-09-14 2003-03-27 Martin F. Bachmann In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
AR045702A1 (en) 2001-10-03 2005-11-09 Chiron Corp COMPOSITIONS OF ASSISTANTS.
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
WO2004015099A2 (en) 2002-08-02 2004-02-19 Glaxosmithkline Biologicals Sa Vaccine composition comprising lipooligosaccharide with reduced phase variability
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CA2501812C (en) 2002-10-11 2012-07-10 Mariagrazia Pizza Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
ATE466875T1 (en) 2002-11-15 2010-05-15 Novartis Vaccines & Diagnostic UNEXPECTED SURFACE PROTEINS IN NEISSERIA MENINGITIDIS
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
AU2003288558A1 (en) 2002-12-16 2004-07-09 Nasjonalt Folkehelseinstitutt Meningococcal vaccine based on outer membrane proteins porb2 and pora
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
JP5173194B2 (en) 2003-12-23 2013-03-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム vaccine
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
HUE033196T2 (en) 2005-01-27 2017-11-28 Children's Hospital & Res Center At Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
AU2009262893B2 (en) 2008-05-30 2015-05-21 The U.S.A., as represented by The Secretary of the Army, on behalf of Walter Reed Army Institute Of Research Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
GB0816284D0 (en) 2008-09-05 2008-10-15 Nat Biolog Standards Board Vaccine

Also Published As

Publication number Publication date
BRPI0517514A (en) 2008-10-14
JP2016135139A (en) 2016-07-28
CA2584778C (en) 2014-04-08
US10336794B2 (en) 2019-07-02
US20100015212A1 (en) 2010-01-21
JP5362221B2 (en) 2013-12-11
JP2011188870A (en) 2011-09-29
US9771399B2 (en) 2017-09-26
EP2279747A1 (en) 2011-02-02
GB0424092D0 (en) 2004-12-01
EP2279747B1 (en) 2014-06-25
PT2279747E (en) 2014-10-02
WO2006046143A2 (en) 2006-05-04
US20160108094A1 (en) 2016-04-21
AU2005298332B2 (en) 2012-05-03
US20180009852A1 (en) 2018-01-11
WO2006046143A3 (en) 2007-03-15
EP1804834B1 (en) 2011-05-25
JP2008517617A (en) 2008-05-29
ATE510559T1 (en) 2011-06-15
JP2014039566A (en) 2014-03-06
CA2584778A1 (en) 2006-05-04
US9206399B2 (en) 2015-12-08
CN101048175A (en) 2007-10-03
NZ553989A (en) 2010-03-26
JP6077983B2 (en) 2017-02-08
BRPI0517514A8 (en) 2017-10-03
ES2507499T3 (en) 2014-10-15
CN101048175B (en) 2013-03-13
PL2279747T3 (en) 2015-01-30
AU2005298332A1 (en) 2006-05-04
EP1804834A2 (en) 2007-07-11

Similar Documents

Publication Publication Date Title
CY1112105T1 (en) Immunogenic Bacterial Bladders with External Membrane Proteins
CY1111035T1 (en) MICROorganisms as Nucleotide Sequence vectors Encoding Antigens and Protein Toxins, a Method of Industrial Chemical Production
CY1119046T1 (en) CELLULAR MEDICINE WITHOUT OLIGEPTECTS
CY1122131T1 (en) GENETIC IMMUNIZATION TO PRODUCE IMMUNOSPHEREINS AGAINST CELL-ASSOCIATED ANTIGENS, SUCH AS P2X7, CXCR7, OR CXCR4
CY1109230T1 (en) ISOLATION OF COGNITIVE LINENIC ACID AND A PROCEDURE FOR PREPARATION OF COGNITIVE LINENIC ACID
CY1118492T1 (en) NOROVIRUS VACCINE PHARMACEUTICAL FORMS
CY1111591T1 (en) HYBRID EXPRESSION OF NEISSERIA PROTEINS
PL1863920T3 (en) Method for improved isolation of recombinantly produced proteins
DE69838383D1 (en) CULTURE MEDIUM WITH SOYBEAN EXTRACT AS AN AMINO ACID SOURCE AND NO PROTEIN COMPLEX ANIMAL ORIGIN
BRPI0717768B8 (en) antibody, epitope, isolated DNA sequence, cloning or expression vector, process for producing the antibody, pharmaceutical composition, and use of an antibody
AR054477A1 (en) IMMUNIZATION VACCINES AGAINST HELICOBACTER
NO20083266L (en) Human anti-IL-23 antibodies, compositions, methods and applications
EA200701130A1 (en) ELECTROPORATION OF MYCOBACTERIA AND SUPEREXPRESSION OF MYCOBACTERIA ANTIGENS
CY1112654T1 (en) BACTERIAL COVER SHAPE FORMAT
MX2010002867A (en) Live attenuated mycoplasma strains.
NZ594029A (en) Cna_b domain antigens in vaccines against gram positive bacteria
AR092630A1 (en) METHODS AND COMPOSITIONS TO PREVENT THE WRONG INCORPORATION OF NORLEUCINE IN PROTEINS
CL2011000913A1 (en) Stable and completely liquid combined vaccine comprising diphtheria, tetanus, whole cell pertussis antigens, and poliomyelitis virus and optionally one or more antigens selected from haemophilus influenzae and hepatitis; and manufacturing process.
EA200702092A1 (en) LIPOSOMIC COMPOSITION FOR IMMUNITY INDUCTION
UY27059A1 (en) PREPARATIONS TO POWER THE IMMUNOGENCITY OF LITTLE IMMUNOGENIC ANTIGENS
DE60222807D1 (en) MILK PROTEIN BIOFILM AND USES THEREOF
DK1833507T3 (en) Composition for immunization against mycobacteria
DE602004032143D1 (en) HYBRID TOXINS WITH SHIGA-LIKE TOXIN SUB-UNITS, ASSOCIATED WITH ESCHERICHIA COLI HEAT STABILIZED ENTEROTOXIN SUB-UNITS AND VACCINE THEREOF
WO2018183848A8 (en) Media for microorganism culture and related compositions and methods
CO2023010612A2 (en) Recombinant meningococcal b vaccine